Supplementary Figures 1-5 from Preexisting MEK1<sup>P124</sup> Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

<p>Supplementary Figures 1-5. S1 MEK1 P124 variants activate ERK1/2; S2 MEK1P124Q diminishes BRAF inhibitor sensitivity; S3 Effect of MEK1 mutations on MAPK and PI3K pathway signaling; S4 Identification of MEK1P124Q variant in the SMU030 cell line; S5 Characterisation of melanoma cell lines.</p>